Schrödinger closed an $85m (€74) financing round to support an expansion of its computational platform and drug discovery pipeline for internal and external use.
Elpis Biomed is scaling its proprietary ‘direct cellular reprogramming platform’ – and has its sights set on becoming a global provider of high-quality human cells, with strategic partnerships soon to be announced, says the company’s founder.
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.
Charles River is eyeing M&A opportunities in every segment of its business, fueled by global market demand and a “fundamental shift” in the pharmaceutical industry, says CEO.
Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.
RxCelerate is opening its first office in the US to be closer to clients and meet a "huge demand" for drug discovery and development services in the greater Boston area.
WuXi Biologics and CANbridge Pharmaceutical have entered into a long-term partnership to develop and commercialize a portfolio of biotherapeutics for rare diseases.
Evotec AG and Ferring Pharmaceuticals are collaborating to discover and develop new small molecule therapies for the treatment of fertility and gynaecological conditions.
The platform will be designed to help life sciences organizations improve productivity, efficiency, and innovation in early stage drug development, says Accenture executive.
Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
Antoxerene and investor firm Juvenescence have collaborated to form FoxBio Inc., an offshoot focused on small molecule drug discovery for the pathways of ageing.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
Charles River has been granted commercial access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure, an investment that will help the company "deliver optimal benefit" to its customers, says executive.
Fraunhofer is “redoubling” its efforts to develop new antibiotics and transfer research into clinical trials through a project available to external partners for development.
Biogen and Accenture Labs have collaborated to develop a quantum-enabled molecular comparison application to accelerate drug discovery and ultimately, time to clinic.
AMRI has entered an alliance through which the global contract research and manufacturing organization will gain access to "new avenues of drug discovery."
A US-subsidiary of the Chinese CDMO Porton Fine Chemicals Ltd. has bought the New Jersey based small molecule API contract research organisation, J-STAR Research, Inc.
Sharp Edge Labs will use its propriety biosensor platform to identify lead compounds for Sumitomo Dainippon Pharma – technology that the company says will help focus discussions on outcomes rather than cost.
The Charles Stark Draper Laboratory Inc. has inked a three year partnership with Pfizer to create personalised versions of Draper’s Microphysiological Systems (MPS), for cheaper and more effective preclinical testing.
As part of the company’s continued growth, Charles River’s recent partnership with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will work to accelerate drug development.
Phyton Biotech has developed a cell based way of making thapsigargin, a cytotoxic plant extract that is being developed for the treatment of cancer by Inspyr Therapeutics.
As part of a recent survey, 62% of respondents said they are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago.
More drug discovery work will be outsourced this year according to a report which suggests pharmaceutical industry desire to reduce the risk of failure and cut costs persists.
Researchers have created the first robotically driven experimentation system which reduces the number of necessary experiments throughout drug discovery by 70%.
With the expectation of new regulatory guidelines, and the need for increased productivity, companies will need to become “comfortable with data,” says Quintiles executive.
AMRI has opened a drug discovery center, citing growing customer demand for biology, high-throughput screening, in vitro pharmacology, and medicinal chemistry at a single site.
Evotec has been hired to manage candidate drug compounds by the US National Cancer Institute (NCI) under an agreement the CRO hopes will help it win further contracts.
